Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals has reported Non-Current Assets over the past 3 years, most recently at $833.7 million for Q4 2025.

  • Quarterly Non-Current Assets rose 113.24% to $833.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $833.7 million through Dec 2025, up 113.24% year-over-year, with the annual reading at $833.7 million for FY2025, 125.17% up from the prior year.
  • Non-Current Assets was $833.7 million for Q4 2025 at Telix Pharmaceuticals, up from $391.0 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $833.7 million in Q4 2025 and troughed at $112.9 million in Q4 2023.
  • The 3-year median for Non-Current Assets is $391.0 million (2024), against an average of $445.9 million.
  • Year-over-year, Non-Current Assets surged 246.25% in 2024 and then skyrocketed 113.24% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $112.9 million in 2023, then surged by 246.25% to $391.0 million in 2024, then skyrocketed by 113.24% to $833.7 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Non-Current Assets are $833.7 million (Q4 2025), $391.0 million (Q4 2024), and $112.9 million (Q4 2023).